New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s (Alamy Stock Photo) By Jane Kirby, PA Health Editor June 19, 2025 at 12:01am BST ...

Donanemab In May of 2023, two months prior to the full approval of lecanemab, another promising treatment for the disease, Eli Lilly’s donanemab, emerged from Phase III trials.

In studies the drugs lecanemab and donanemab helped to clear toxic clumps out of the brain and slow nerve damage caused by the illness. An estimated 70,000 people might be eligible if they were ...

Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way, but fortnightly.

Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly.

Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.

Two drugs – donanemab and lecanemab – have been rejected for NHS use because their benefits are "too small" to justify their cost Comments News Bethan Finighan 00:01, 19 Jun 2025 More than ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...